AB-161
AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2848560-66-5
- Fòrmula: C21H21F2N3O5
- Peso molecular:433.41
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
Chemical Information
-
No. CAS 2848560-66-5
-
Peso molecular 433.41
-
Fòrmula C21H21F2N3O5
-
SMILES
O=C(O)C1=CC2=C(C3=C(C[C@H]2C(C)(C)C)N4C(C(OC(F)F)=CC(OC)=C4)=N3)NC1=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureza y Documentación
-
Ficha de datos (271 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Gotchev D, et al. Structure-Activity Relationships and Discovery of (S)-5-(tert-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-h]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA Destabilizer. J Med Chem. 2024 Nov 28;67(22):20467-20494. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AB-161 Related Classifications
HY-159987 Related Classifications
Powered by Bioz